Literature DB >> 11137107

Frequency of the R3500Q mutation of the apolipoprotein B-100 gene in a sample screened clinically for familial hypercholesterolemia in Hungary.

A Kalina1, A Császár, A E Czeizel, L Romics, F Szabóki, C Szalai, I Reiber, A Németh, S Stephenson, R R Williams.   

Abstract

Familial hypercholesterolemia (FH) and familial defective apolipoprotein B-100 (FDB) cause early onset of coronary heart diseases (CHD). According to the recommendations of the international MEDPED program, we tried to find FH cases. We analyzed 73 FH probands and their 304 first-degree relatives. A total of 39 probands were found from the 21000 subjects screened (1:538) from family doctors' registers recording all citizens, while the remaining 34 were derived from screened patients from lipid clinics. In our FH probands, four cases of FDB (R3500Q mutation) were diagnosed with allele-specific PCR, and the mutation was also detectable in five cases out of seven living family members. In the remaining 69 FH families, 156 people were diagnosed clinically with FH, and 31.8% of the males (against 13% of the not clinically diagnosed FH males, P<0.01), and 32.4% of the females (against 13.5% of the not clinically diagnosed FH females, P<0.01) suffered from early onset CHD. The plasma total cholesterol level of the FDB patients, especially in the younger patients, was very close to normal values. Therefore, the FDB patients seem to be under-represented in this type of survey. Because FDB is one of the independent causes of early onset CHD, the R3500Q mutation should be considered in families with a high frequency of cardiovascular diseases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11137107     DOI: 10.1016/s0021-9150(00)00648-1

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  5 in total

1.  Molecular characterization of Polish patients with familial hypercholesterolemia: novel and recurrent LDLR mutations.

Authors:  M Chmara; B Wasag; M Zuk; J Kubalska; A Wegrzyn; M Bednarska-Makaruk; E Pronicka; H Wehr; J C Defesche; A Rynkiewicz; J Limon
Journal:  J Appl Genet       Date:  2010       Impact factor: 3.240

Review 2.  Familial Hypercholesterolemia: New Horizons for Diagnosis and Effective Management.

Authors:  Maria Mytilinaiou; Ioannis Kyrou; Mike Khan; Dimitris K Grammatopoulos; Harpal S Randeva
Journal:  Front Pharmacol       Date:  2018-07-12       Impact factor: 5.810

Review 3.  Molecular diagnosis methods in familial hypercholesterolemia.

Authors:  Valeriu Moldovan; Claudia Banescu; Minodora Dobreanu
Journal:  Anatol J Cardiol       Date:  2020-02       Impact factor: 1.596

Review 4.  Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis.

Authors:  Leo E Akioyamen; Jacques Genest; Shubham D Shan; Rachel L Reel; Jordan M Albaum; Anna Chu; Jack V Tu
Journal:  BMJ Open       Date:  2017-09-01       Impact factor: 2.692

5.  Establishing the Mutational Spectrum of Hungarian Patients with Familial Hypercholesterolemia.

Authors:  László Madar; Lilla Juhász; Zsuzsanna Szűcs; Lóránt Kerkovits; Mariann Harangi; István Balogh
Journal:  Genes (Basel)       Date:  2022-01-15       Impact factor: 4.096

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.